How to Find a Legitimate Retatrutide Clinical Trial
Short answer: The only legal way to access retatrutide in the United States is through an authorized clinical trial registered on ClinicalTrials.gov. Trials are free to participate in, medically supervised, and use pharmaceutical-grade drug. This page explains how to find one, what to expect, and how to screen for eligibility.
Quick Answers
How do you get retatrutide prescribed?
Retatrutide cannot be prescribed. It is an investigational drug that has not received FDA approval. No licensed physician can legally write a prescription for retatrutide outside of an authorized clinical trial. The only legal way to access retatrutide is through a registered trial on ClinicalTrials.gov, where it is administered under medical supervision at no cost to participants.
Eli Lilly plans to submit a regulatory application to the FDA in Q1 2027. Until approval, no prescription pathway exists. See the availability timeline for the expected approval window, and FDA regulatory status for the current approval pathway.
Who prescribes retatrutide?
No physician can prescribe retatrutide outside of a clinical trial — it is not FDA-approved. Within authorized trials, principal investigators and sub-investigators at licensed research sites administer the drug under an FDA-approved Investigational New Drug (IND) application. After approval, obesity medicine specialists and endocrinologists are the most likely prescribers.
To find a physician currently authorized to administer retatrutide, search ClinicalTrials.gov for active TRIUMPH trials and contact the study coordinator at a site near you. See the step-by-step enrollment process below.
Can a telehealth provider prescribe retatrutide?
No. Telehealth providers cannot prescribe retatrutide. Any telehealth company claiming to prescribe or provide retatrutide is operating outside federal law. Retatrutide has no approved NDA and cannot be legally dispensed by any pharmacy or telehealth service as of September 2026. The FDA has issued warning letters to vendors of unapproved GLP-1 compounds.
For more on the legal landscape: Can Retatrutide Be Compounded? and Online Retatrutide and Peptide Sellers.
Can my doctor prescribe retatrutide?
No. Retatrutide is not FDA-approved and cannot be prescribed by any physician in a standard clinical setting. If your doctor is a principal investigator at an authorized trial site, they may be able to enroll you in a clinical trial — but that is participation in a research study, not a standard prescription. Ask your doctor if their practice is affiliated with a TRIUMPH trial site.
If you want to discuss retatrutide with your doctor, our Questions for Your Doctor guide provides a framework for that conversation.
The 7-Step Enrollment Process
Why Clinical Trials Are the Only Legal Pathway
Retatrutide is an investigational drug. It has not received FDA approval and is not commercially available. The only legal mechanism for a person to receive retatrutide is through a clinical trial operating under an FDA Investigational New Drug (IND) application — a formal authorization that permits a sponsor to administer an unapproved drug to human subjects under controlled conditions.
Clinical trial participants receive pharmaceutical-grade retatrutide manufactured under strict GMP standards, with verified purity, sterility, and concentration. They receive it at no cost, under the supervision of licensed investigators at FDA-approved research sites, with full adverse event monitoring and medical support.
No online vendor, compounding pharmacy, or peptide seller can legally provide retatrutide. Any product sold outside of an authorized trial is an unapproved drug with no quality guarantees and no legal standing.
How to Search ClinicalTrials.gov
ClinicalTrials.gov is the official US registry of clinical studies, maintained by the National Library of Medicine. Every authorized retatrutide trial in the United States must be registered here. The registry is free to search and updated continuously.
To find retatrutide trials, go to ClinicalTrials.gov and search for 'retatrutide' in the condition or intervention field. Filter by status — 'Recruiting' shows trials actively enrolling participants. You can also filter by location to find sites near you.
Each trial listing includes the NCT number (a unique identifier), the sponsor, the phase, eligibility criteria, participating sites, and contact information for the study coordinator. The study coordinator is your primary point of contact for screening and enrollment questions.
The TRIUMPH Trial Program
The TRIUMPH trials are Eli Lilly's Phase 3 clinical program for retatrutide in obesity and related conditions. TRIUMPH-1 and TRIUMPH-2 are the pivotal trials evaluating retatrutide for chronic weight management. Additional TRIUMPH trials are evaluating retatrutide in type 2 diabetes, obstructive sleep apnea, and cardiovascular outcomes.
TRIUMPH trials are conducted at licensed research sites across the United States and internationally. Site availability varies — not all sites are recruiting at all times. Check the ClinicalTrials.gov listing for each TRIUMPH trial to see which sites are currently enrolling.
View all TRIUMPH trials →Typical Eligibility Criteria
Eligibility criteria vary by trial and phase. Phase 3 trials like TRIUMPH typically have broader eligibility than earlier-phase studies. The following criteria are representative of retatrutide obesity trials — always verify against the specific trial listing.
| Criterion | Typical requirement | Notes |
|---|---|---|
| Age | 18 years or older | Some trials specify 18–75; verify per listing |
| BMI | BMI ≥ 30, or ≥ 27 with a weight-related comorbidity | Comorbidities may include hypertension, dyslipidemia, or prediabetes |
| Type 2 diabetes | Varies by trial arm | Some trials exclude T2D; others specifically enroll T2D patients |
| Prior GLP-1 use | Often excluded or requires washout period | Recent use of semaglutide or tirzepatide may disqualify |
| Cardiovascular history | Varies — some trials exclude recent CV events | TRIUMPH-CV specifically enrolls high-CV-risk patients |
| Pregnancy / breastfeeding | Excluded | Standard exclusion for all GLP-1 trials |
| Renal / hepatic impairment | Severe impairment typically excluded | Moderate impairment criteria vary by trial |
| Personal or family history of MTC or MEN2 | Excluded | Standard exclusion for all GLP-1 receptor agonist trials |
Always verify eligibility criteria against the specific ClinicalTrials.gov listing for the trial you are interested in. Criteria vary by trial and may change as protocols are amended.
What to Expect: The Enrollment Process
Finding a trial and enrolling are separate steps. Expressing interest does not guarantee enrollment — you must pass a screening visit where the research team verifies your eligibility against the protocol criteria.
The process typically takes two to six weeks from initial contact to first dose, depending on the trial's screening schedule and how quickly screening visits can be arranged. Some trials have waitlists if enrollment is near capacity.
Once enrolled, you will sign an informed consent document that explains the study protocol, your rights as a participant, what the drug is, what is known about its effects, and what risks have been identified. You may withdraw at any time without penalty.
Warning: third-party trial matching services
Some websites offer to match you with clinical trials for a fee, or collect your personal information to sell to sponsors. You do not need a third-party service to find or enroll in a retatrutide trial. Use ClinicalTrials.gov directly and contact the study coordinator listed on the trial record.
Legitimate trials never charge participation fees. If a service asks you to pay to join a trial, it is not legitimate.
Frequently Asked Questions
How do I get retatrutide prescribed?
Retatrutide cannot be prescribed. It is an investigational drug that has not received FDA approval. No licensed physician can legally write a prescription for retatrutide outside of an authorized clinical trial. The only legal way to access retatrutide is through a registered trial on ClinicalTrials.gov, where it is administered under medical supervision.
Who prescribes retatrutide?
No physician can prescribe retatrutide outside of a clinical trial — it is not FDA-approved. Within authorized trials, principal investigators and sub-investigators at licensed research sites administer the drug under an FDA-approved Investigational New Drug (IND) application. These are not prescriptions in the commercial sense.
Can a telehealth provider prescribe retatrutide?
No. Telehealth providers cannot prescribe retatrutide. Any telehealth company claiming to prescribe or provide retatrutide is operating outside federal law. Retatrutide has no approved NDA and cannot be legally dispensed by any pharmacy or telehealth service as of September 2026.
Can my doctor prescribe retatrutide?
No. Retatrutide is not FDA-approved and cannot be prescribed by any physician in a standard clinical setting. If your doctor is a principal investigator at an authorized trial site, they may be able to enroll you in a clinical trial — but that is participation in a research study, not a standard prescription.
How do I find a retatrutide doctor or specialist?
Search ClinicalTrials.gov for active retatrutide trials and contact the listed study coordinators at trial sites near you. These are the only physicians legally authorized to administer retatrutide. After FDA approval, obesity medicine specialists and endocrinologists are the most likely prescribers.
Is it free to participate in a retatrutide clinical trial?
Yes. Clinical trial participants receive the study drug at no cost. In most trials, study-related visits, labs, and procedures are also covered by the sponsor. You should never pay to participate in a legitimate clinical trial.
How do I know if a clinical trial is legitimate?
Every authorized US clinical trial must be registered on ClinicalTrials.gov and assigned an NCT number. Verify the NCT number on the registry before engaging with any trial site. Legitimate trials never charge participation fees, never ask you to purchase the drug yourself, and always require informed consent before any procedures.
What is the TRIUMPH trial program?
TRIUMPH is Eli Lilly's Phase 3 clinical program for retatrutide. It includes pivotal obesity trials (TRIUMPH-1 and TRIUMPH-2), as well as trials in type 2 diabetes, obstructive sleep apnea, and cardiovascular outcomes. TRIUMPH trials are conducted at licensed research sites across the US and internationally.
What BMI do I need to qualify for a retatrutide trial?
Most retatrutide obesity trials require a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related comorbidity such as hypertension, dyslipidemia, or prediabetes. Exact criteria vary by trial — always verify against the specific ClinicalTrials.gov listing.
Can I join a trial if I have previously used semaglutide or tirzepatide?
It depends on the trial. Many retatrutide trials require a washout period after prior GLP-1 receptor agonist use, or exclude recent users entirely. Check the exclusion criteria on the ClinicalTrials.gov listing for the specific trial you are interested in.
How long does the enrollment process take?
Typically two to six weeks from initial contact to first dose, depending on the trial's screening schedule and site availability. Some trials have waitlists if enrollment is near capacity.
Can I withdraw from a trial after enrolling?
Yes. Participation in a clinical trial is always voluntary. You may withdraw at any time without penalty and without affecting your access to other medical care. This right is explained in the informed consent document you sign before enrollment.
Are there retatrutide trials outside the United States?
Yes. The TRIUMPH program includes international sites. ClinicalTrials.gov lists international sites for each trial. You can filter by country on the registry.